Effective Assessment of Diabetes Control Using Personal Glucometers (CONTOURLINK, Bayer, Germany; CALLA, Wellion, Austria; LINUS, Agamatrix, USA)

Abstract

Aim of this trial was to assess (1) the accuracy and precision of electrochemistry-based glucometers CONTOURLINK, CALLA, and LINUS and (2) the diabetes control using Ambulatory Glycaemic Profiles (AGP) as markers of therapeutic effectiveness. Glucometers and COBAS INTEGRA 400 Plus analyzer were used by one laboratory professional to estimate P-glucose (PG) in 112 out-patients. There were 112 sets of 12 PG estimations analyzed. In each set, means of 3 capillary PG estimations on 3 respective glucometers and on INTEGRA analyzer were calculated. The statistical program SPSS, v. 15, was applied. The mean INTEGRA PG values ranged from 2.7 to 25.3 mmol/L. There were strong correlations between mean PG on INTEGRA versus CONTOURLINK, versus CALLA, and versus LINUS; PG deviations from INTEGRA were mostly within the range ±15%. Wilcoxon Signed Rank Test revealed differences between CONTOURLINK-INTEGRA and LINUS-INTEGRA; CALLA-INTEGRA showed no difference. SD INTEGRA = 0.061 mmol/L, SD CONTOURLINK/SD CALLA/SD LINUS were 0.256/0.290/0.286 mmol/L. All patients were trained to perform defined 10-point PG profiles to adapt food, exercise, and insulin doses. The PG differences between all tested glucometers and reference values were in borderline of ISO 15197 but worthy of consideration. AGP are helpful markers of diabetes control.

SGLT1 activity in lung alveolar cells of diabetic rats modulates airway surface liquid glucose concentration and bacterial proliferation

“…Glucose concentration in BAL samples was measured using the COBAS Integra 400 (Roche Diagnostics GmbH, Mannheim), with the Glucose HK Gen.3 assay (Roche Diagnosis) 42 . Blood glucose concentration was measured by a glucometer (Precision QID, MediSense, Sao Paulo, SP, Brazil).…”

Glucose concentrations in blood and tissue - a pilot study on variable time lag

“…From1974, following the introduction of glucometers into daily routine, self-monitoring of plasma/ blood glucose (SMPG/SMBG) became the predominant mode of glucose monitoring 6 . From the year 2000, the use of continuous glucose monitoring systems (CGMS) has shown remarkable benefits for both people with type 1 and type 2 diabetes [7][8][9][10][11][12] .…”

Pathophysiologic Approach to Type 2 Diabetes Management: One Centre Experience 1980–2020

“…Strong correlations between PG values estimated on COBAS INTEGRA analyser vs. individual glucometers (CONTOURLINK, CALLA, LINUS) were shown (Figure 7). Correlations (Spearman) between PG estimations on INTEGRA vs. CALLA [19] Deviations from INTEGRA were within the range ± 15%. (Figure 8) PG variability was measured by SD: SD INTEGRA = 0.061 mmol/l, SD CONTOURLINK = 0.256 mmol/l, SD CALLA = 0.290 mmol/l, SD LINUS = 0.286 mmol/l.…”

“…The purpose of our last experimental and clinical trial (2010-2013) [19] was (1) to assess the electrochemistry-based glucometers CONTOURLINK (Bayer, Germany) using glucose dehydrogenase strips, CALLA, (Wellion, Austria) and LINUS (Agamatrix, USA) both using glucose oxidase strips; (2) to evaluate diabetes control using Ambulatory Glycaemic Profiles (AGP) and comparing the results with those of the COBAS INTEGRA 400 Plus analyser. There were 112 sets (each from one person) analysed.…”

“…[12][13][14] Despite of pumps many persons with T2D were unable to reach the expected metabolic improvement until incretin receptor agonists and gliflozins have been made available. [15,16] In 1974, the first glucometer (Ames) was introduced into clinical practice, followed by tenths of other glucometers [17][18][19], Continuous Glucose Monitors (CGM) [20] and/or Flash Glucose Monitors (FGM) [21]. Today, these devices have become mandatory means (together with HbA1c analysers [22]) to assess the metabolic control.…”